ATNF — 180 Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00
- $1.55m
- $0.63m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.547 | 2.11 | 8.22 | 6.97 | 1.98 |
Net Total Receivables | 0.026 | 0.799 | 0.695 | 0.621 | 0.45 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.624 | 4.01 | 11.2 | 8.93 | 3.64 |
Net Property, Plant And Equipment | — | 0 | — | — | — |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 12.5 | 55.5 | 62.7 | 19.7 | 5.26 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.13 | 21.5 | 19.7 | 5.66 | 5.06 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 7.15 | 25.2 | 23.4 | 8.31 | 5.39 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 5.35 | 30.3 | 39.3 | 11.3 | -0.128 |
Total Liabilities & Shareholders' Equity | 12.5 | 55.5 | 62.7 | 19.7 | 5.26 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |